The invention in this patent application relates to spirocyclopropane-2-carboxamide derivatives represented generally by formula 1. These compounds are positive allosteric modulators of α7 nAChR and may be useful in preventing, treating, or ameliorating central nervous system diseases and disorders such as cognitive impairments in Alzheimer's disease, Parkinson's disease, schizophrenia, and L-DOPA-induced dyskinesia as well as inflammation and cough.
No takes yet. Share an insight, caveat, or question.
Ahmed F. Abdel‐Magid (2023) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: